Clinical Trial Goal
To find out if the combination of epcoritamab and tazemetostat is safe and works well to treat follicular lymphoma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have follicular lymphoma, grade 1 - 3b, that has relapsed or is refractory
- Do not have lymphoma in your brain or spinal cord
- Have not been treated any of the following. Your doctor can tell you this:
- Bispecific antibodies
- Tazemetostat
- Do not have graft-versus-host-disease (GVHD)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Epcoritamab is a bispecific monoclonal antibody that targets CD3 and CD20 on certain cells.
Tazemetostat is a small molecule inhibitor that blocks EZH2 in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
Tazemetostat is a small molecule inhibitor that blocks EZH2 in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- Epcoritamab – Given as a shot under your skin up to 1 time each week
- Tazemetostat – A pill that you take by mouth 2 times each day
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 3 years.
The Food and Drug Administration (FDA) has approved epcoritamab and tazemetostat to treat follicular lymphoma that has relapsed or is refractory. Using them in this combination is new and unproven.
Locations
City of Hope at Irvine LennarNOT_YET_RECRUITING
Irvine, California
Swetha Kambhampati, 626-256-4673, skambhampati@coh.org
City of Hope Medical CenterRECRUITING
Duarte, California
Swetha Kambhampati, 626-256-4673, skambhampati@coh.org
Sponsors
collaborator: National Cancer Institute (NCI), lead: City of Hope Medical Center
